Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2012.542 | Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis | Prof. SZETO Cheuk Chun |
| 2013.253 | Intra-Renal and Urinary Th9 and Th22 Cytokine Gene Expression in Lupus Nephritis | Prof. Szeto Cheuk Chun |
| 2012.122 | The role of Extracellular Microvesicle miR-21 as a Mediator Of Progressive Renal Tubulointerstital Fibrosis | Prof. Szeto Cheuk Chun |
| 2008.276 | Genetic Determinants of Peritoneal Transport Characteristics, Peritonitis and Cardiovascular Risk for Chronic Peritoneal Dialysis Patients | Prof. SZETO Cheuk Chun |
| 2012.050 | Long-Term Outcome of Biopsy-Proven Minimal-Change Nephrotic Syndrome in Adult | Prof. SZETO Cheuk Chun |
| 2009.246 | Outcome of Hemodialysis Patients Who had Failed Peritoneal Dialysis | Prof. SZETO Cheuk Chun |
| 2012.048 | Long-Term Outcome of Biopsy-Proven Minimal-Change Nephrotic Syndrome in Children | Prof. SZETO Cheuk Chun |
| 2010.376 | Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis | Prof. SZETO Cheuk Chun |
| 2012.541 | Circulating Mitochondrial-Derived DNA Fragments: A Possible Factor in the Pathophysiology of Systemic Inflammation and Cardiovascular Disease in Chronic Kidney Disease? | Prof. SZETO Cheuk Chun |
| 2009.359 | Bacteria-Derived DNA Fragment in Peritoneal Dialysis Effluent as a Predictor of Relapsing Peritonitis | Prof. SZETO Cheuk Chun |
| 2008.378 | Acute-on-Chronic Renal Failure: Indenticiation of Urinary Biomarkers for the Prediction of Reversibility | Dr. SZETO Cheuk Chun |
| 2010.375 | Circulating Bacterial-Derived DNA Fragments in Peritoneal Dialysis | Prof. SZETO Cheuk Chun |
| 2009.356 | Circulating Bacterial-Derived DNA Fragments and Markers of Iinflammation in Peritoneal Dialysis Patients | Prof. SZETO Cheuk Chun |
| 2011.253 | Relation Between microRNA Expression in Peritoneal Dialysis Effluent and Peritoneal Transport Characteristics | Prof. SZETO Cheuk Chun |
| 2010.186 | In-Depth Analysis of Patients Who Missed the Appointment of general Medical Clinic | Prof. SZETO Cheuk Chun |
| 2010.405 | The effect of using ultrapure water for hemodialysis on the circulating levels of bacterial endotoxin and proinflammatory cytokines | Prof. SZETO Cheuk Chun |
| 2010.173 | Relation Between Intra-Renal Cytokine Expression and Histological Class of Lupus Nephritis | Prof. SZETO Cheuk Chun |
| 2012.311 | Patients Who Default From Follow-up at Renal Specialist Clinic: Characteristics and Prognostic Implications | Prof. SZETO Cheuk Chun |
| 2013.530 | Determining the Role of microRNA in Peritoneal Fibrosis by ex vivo Mesothelial Cell Culture from Peritoneal Dialysis Patients | Professor Szeto Cheuk Chun |
| 2009.188 | The Effect of Neutral Peritoneal Dialysis Solution with Minimal Glucose-Degradation-Product on the Body Composition - A Cross-Sectional Study | Prof. SZETO Cheuk Chun |
| 2008.257 | Monitoring of Urinary Messenger RNA Expression for the Prediction of Flare in Systemic Lupus Erythematosus | Prof Szeto Cheuk Chun |
| 2013.532 | A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-dialysis Patients | Professor SZETO Cheuk Chun |
| 2010.164 | TRK-100STP Phase Iib/III Clinical Study Protocol | Prof. SZETO Cheuk Chun |
| 2014.242 | Treatment of Asymptomatic Fluid Overload in Peritoneal Dialysis Patients | Professor Szeto Cheuk Chun |
| 2013.564 | A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis | Prof. SZETO Cheuk Chun |
| 2010.278 | Hemoglobin Variability in Chinese Pre-Dialysis CKD Patients Not Reciving Erythropoietin | Prof. SZETO Cheuk Chun |
| 2009.355 | The Effect of Neutral Peritoneal Dialysis Solution With Minimal Glucose-Degradation-Product on the Fluid Status and Body Composition | Prof. SZETO Cheuk Chun |
| 2021.566 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease | Prof. SZETO Cheuk Chun |
| 2021.020 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.740 | Fluid Overload as the Cause of Gut Permeability Barrier Dysfunction in Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.562 | Urinary Biomarkers for the Early Diagnosis and Prognostic Indicators of Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2022.159 | Optimization of Peritoneal Dialysis Prescription by Early Determination of Peritoneal Transport Characteristics |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.163 | Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with non-diabetic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.170 | Development of a novel risk score for the prognosis of IgA nephropathy |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.367 | The Prognostic Role of Volume Overload in New Peritoneal Dialysis Patients |
Prof Szeto Cheuk Chun 司徒卓俊 |
| 2022.206 | The Relation Between Glycemic Variability on Renal Mitochondrial Injury in Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2022.684 | SGLT2 Inhibitor and DPP-4 Inhibitor for Podocyte Protection in Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.363 | Modified Creatinine Index as a Non-Invasive Tool for the Monitoring of Muscle Mass in Peritoneal Dialysis |
Prof. SZETO Cheuk Chun Szeto Cheuk Chun |
| 2023.641 | Peritoneal Leukocyte Load as Predictor of Peritoneal Membrane Failure |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.247 | A multicentered, single-group Phase 2, exploratory, open-label study to investigate safety and effect of sparsentan in combination with sodium glucose cotransporter-2 (SGLT2) inhibition in the treatment of adult participants with Immunoglobulin A nephropathy (IgAN) |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.738 | Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊教授 |
| 2020.601 | Optimization of Urine Processing for Biomarker Development of Kidney Diseases |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.271 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects with IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy including Dense Deposit Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2019.363 | Intra-renal miR-21 expression in IgA nephropathy |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2020.643 | The Efficacy and Safety of SGLT2 Therapy in Advanced Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2020.224 | Optimal Strategy for the Monitoring of Dialysis Adequacy in Peritoneal Dialysis Patients |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2019.646 | Regulation of Peritoneal Transport by the Cyclooxygenase Pathway and Its Pharmacological Modulation |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2019.283 | The role of Activating Transcription Factor 5 (ATF5) for mitochondrial protection in diabetic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.333 | A Randomized, Multicenter, Double-Blind, Parallel-Group, Active-Control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy |
Prof SZETO Cheuk Chun 司徒卓俊 |
| 2018.245 | Defining the Optimal Duration of Treatment for “Low-Risk” Peritoneal Dialysis-Related Peritonitis |
Prof. SZETO Cheuk Chun 司徒卓俊 |
Page 62 of 254.